Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo takes on tough lung cancer in early trial

NCT ID NCT05990738

Ongoing Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Feb 26, 2026

Summary

This early-phase trial tests a new antibody-like drug called BI 764532 (Obrixtamig) combined with standard chemotherapy in about 69 adults with advanced small cell lung cancer that has returned after platinum-based treatment. The main goal is to find the highest safe dose of the combination. Researchers will also watch for tumor shrinkage and how long any response lasts.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CARCINOMA (SCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • HOP Civil

    Strasbourg, 67091, France

  • INS Curie

    Paris, 75005, France

  • Institut Gustave Roussy

    Villejuif, 94805, France

  • Leicester Royal Infirmary

    Leicester, LE1 5WW, United Kingdom

  • Mayo Clinic - Florida

    Jacksonville, Florida, 32224, United States

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia, 20007, United States

  • Polish Mother's Memorial Hospital - Research Institute

    Lodz, 93-338, Poland

  • Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg

    Heidelberg, 69126, Germany

  • University of Miami

    Miami, Florida, 33136, United States

  • Universitätsklinikum Carl Gustav Carus Dresden

    Dresden, 01307, Germany

  • Universitätsklinikum Erlangen

    Erlangen, 91054, Germany

  • Universitätsklinikum Würzburg AÖR

    Würzburg, 97078, Germany

  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz

    Mainz, 55131, Germany

  • Virginia Commonwealth University

    Richmond, Virginia, 23219, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

BI 764532 (Obrixtamig) plus topotecan or other single-agent chemotherapy

What this could lead to

If it works, this could point toward a new combination treatment for small cell lung cancer that has stopped responding to standard chemotherapy.

What could go wrong

This is an early Phase 1 trial with only 69 participants, focused on safety and dosing. It is too small to prove effectiveness, and side effects from the combination may limit its use.

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMALL CELL LUNG CARCINOMA (SCLC)